Genmab A/S (OTCMKTS:GNMSF) Releases Earnings Results, Beats Estimates By $1.43 EPS

Key Points

• Genmab A/S reported a quarterly earnings of $5.42 EPS, exceeding the consensus estimate of $3.99 EPS by $1.43.
• The company's revenue for the quarter was $925.00 million, falling short of analysts' expectations of $949.06 million.
• Genmab A/S has a market capitalization of $14.29 billion and a price-to-earnings ratio of 10.86.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) issued its quarterly earnings data on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.99 by $1.43, Zacks reports. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The company had revenue of $925.00 million during the quarter, compared to the consensus estimate of $949.06 million.

Genmab A/S Price Performance

Shares of GNMSF stock remained flat at $216.31 during trading hours on Thursday. 100 shares of the stock traded hands, compared to its average volume of 522. The company has a 50 day moving average of $215.56 and a 200 day moving average of $206.96. Genmab A/S has a 52 week low of $170.00 and a 52 week high of $282.06. The stock has a market cap of $14.29 billion, a P/E ratio of 10.86 and a beta of 0.93.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.